PPARβ/δ promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling

Oncogene

Volumn 33, Issue 46, 2014, Pages 5348-5359

  Zhu, B ^a   Ferry, C H ^a   Blazanin, N ^a   Bility, M T ^a   Khozoie, C ^a   Kang, B H ^b   Glick, A B ^a   Gonzalez, F J ^c   Peters, J M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b Chemon Inc   (South Korea)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HRAS induced senescence; inhibition of tumorigenesis; mechanisms of senescence; peroxisome proliferator activated receptor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN KINASE B; RAS PROTEIN;

3T3 CELL LINE; AGING; ANIMAL; CARCINOGENESIS; CELL AGING; CELL CULTURE; CYTOLOGY; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; KERATINOCYTE; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN TUMOR; WESTERN BLOTTING;

AGING; ANIMALS; BLOTTING, WESTERN; CARCINOGENESIS; CELL AGING; CELLS, CULTURED; FEMALE; HEK293 CELLS; HUMANS; KERATINOCYTES; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NIH 3T3 CELLS; PHOSPHORYLATION; PPAR DELTA; PPAR-BETA; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 85027919223     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.477     Document Type: Article

References (72)

1. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 2006; 18: 9–20. DOI: 10.1016/j.cellsig.2005.07.009
2. Peters JM, Shah YM, Gonzales FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012; 12: 181–195. DOI: 10.1038/nrc3214
3. Kilgore KS, Billin AN. PPARβ/δ ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008; 9: 463–469.
4. Grimaldi PA. Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptor β. Curr Opin Lipidol 2010; 21: 186–191. DOI: 10.1097/MOL.0b013e32833884a4
5. Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits chemically-induced skin tumorigenesis. Carcinogenesis 2008; 29: 2406–2414. DOI: 10.1093/carcin/bgn219
6. Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci 2010; 113: 27–36. DOI: 10.1093/toxsci/kfp212
7. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM et al. Peroxisome proliferator-activated receptor β (δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 2004; 279: 23719–23727. DOI: 10.1074/jbc.M312063200
8. Zhu B, Bai R, Kennett MJ, Kang BH, Gonzalez FJ, Peters JM et al. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase 2. Mol Cancer Ther 2011; 9: 3267–3277. DOI: 10.1158/1535-7163.MCT-10-0820
9. Zhu B, Khozoie C, Bility MT, Ferry CH, Blazanin N, Glick AB et al. Peroxisome proliferator-activated receptor β/δ cross talks with E2F and attenuates mitosis in HRAS-expressing cells. Mol Cell Biol 2012; 32: 2065–2082. DOI: 10.1128/MCB.00092-12
10. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986; 322: 78–80. DOI: 10.1038/322078a0
11. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295–308. DOI: 10.1038/nrc2109
12. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593–602. DOI: 10.1016/S0092-8674(00)81902-9
13. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008; 27: 2801–2809. DOI: 10.1038/sj.onc.1210950
14. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 1990; 87: 538–542. DOI: 10.1073/pnas.87.2.538
15. Roop DR, Lowy DR, Tambourin PE, Strickland J, Harper JR, Balaschak M et al. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 1986; 323: 822–824. DOI: 10.1038/323822a0
16. Morgan D, Welty D, Glick A, Greenhalgh D, Hennings H, Yuspa SH et al. Development of an in vitro model to study carcinogen-induced neoplastic progression of initiated mouse epidermal cells. Cancer Res 1992; 52: 3145–3156.
17. Vijayachandra K, Lee J, Glick AB. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res 2003; 63: 3447–3452.
18. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642. DOI: 10.1038/436642a
19. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007; 128: 295–308. DOI: 10.1016/j.cell.2006.11.050
20. de Keizer PL, Packer LM, Szypowska AA, Riedl-Polderman PE, van den Broek NJ, de Bruin A et al. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res 2010; 70: 8526–8536. DOI: 10.1158/0008-5472.CAN-10-1563
21. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374–379. DOI: 10.1038/nature08815
22. Schramek H, Feifel E, Healy E, Pollack V. Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells. J Biol Chem 1997; 272: 11426–11433. DOI: 10.1074/jbc.272.17.11426
23. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 21843–21850. DOI: 10.1074/jbc.M109745200
24. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410–7425. DOI: 10.1038/sj.onc.1209086
25. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78: 961–970. DOI: 10.1124/mol.110.065714
26. Busuttil V, Droin N, McCormick L, Bernassola F, Candi E, Melino G et al. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA 2010; 107: 18061–18066. DOI: 10.1073/pnas.1006163107
27. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10: 459–472. DOI: 10.1016/j.ccr.2006.10.003
28. Sharma A, Luke CT, Dower NA, Stone JC, Lorenzo PS. RasGRP1 is essential for ras activation by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate in epidermal keratinocytes. J Biol Chem 2010; 285: 15724–15730. DOI: 10.1074/jbc.M109.100016
29. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 2004; 279: 34411–34420. DOI: 10.1074/jbc.M403058200
30. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261–269. DOI: 10.1016/S0960-9822(06)00122-9
31. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276: 27462–27469. DOI: 10.1074/jbc.M102940200
32. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal 2007; 19: 1163–1171. DOI: 10.1016/j.cellsig.2006.12.007
33. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res 2006; 66: 4394–4401. DOI: 10.1158/0008-5472.CAN-05-4277
34. Yang L, Olsson B, Pfeifer D, Jönsson JI, Zhou ZG, Jiang X et al. Knockdown of peroxisome proliferator-activated receptor-β induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells. Oncogene 2010; 29: 516–526. DOI: 10.1038/onc.2009.370
35. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009; 1: 236–248. DOI: 10.1002/emmm.200900027
36. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133: 1019–1031. DOI: 10.1016/j.cell.2008.03.039
37. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000; 119: 929–942. DOI: 10.1053/gast.2000.17952
38. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–1765. DOI: 10.1056/NEJMoa0804385
39. Satyanarayana A, Greenberg RA, Schaetzlein S, Buer J, Masutomi K, Hahn WC et al. Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol 2004; 24: 5459–5474. DOI: 10.1128/MCB.24.12.5459-5474.2004
40. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12: 2997–3007. DOI: 10.1101/gad.12.19.2997
41. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42: 36–49. DOI: 10.1016/j.molcel.2011.02.020
42. Alexander K, Hinds PW. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol 2001; 21: 3616–3631. DOI: 10.1128/MCB.21.11.3616-3631.2001
43. Cao X, Xue L, Han L, Ma L, Chen T, Tong T et al. WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) delays cellular senescence by promoting p27(Kip1) degradation in human diploid fibroblasts. J Biol Chem 2011; 286: 33447–33456. DOI: 10.1074/jbc.M111.225565
44. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14: 146–155. DOI: 10.1016/j.ccr.2008.06.002
45. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261–1274. DOI: 10.1016/j.cell.2007.06.009
46. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003; 9: 4409–4414.
47. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009; 69: 6299–6306. DOI: 10.1158/0008-5472.CAN-09-0820
48. Yu J, Shi R, Zhang D, Wang E, Qiu X. Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Archiv Int J Pathol 2011; 458: 99–107. DOI: 10.1007/s00428-010-1016-3
49. Adhikary T, Kaddatz K, Finkernagel F, Schönbauer A, Meissner W, Scharfe M et al. Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). PLoS One 2011; 6: e16344. DOI: 10.1371/journal.pone.0016344
50. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 2002; 99: 2613–2618. DOI: 10.1073/pnas.052707099
51. Peters JM, Foreman JE, Gonzalez FJ. Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast and lung carcinogenesis. Cancer Metastasis Rev 2011; 30: 619–640. DOI: 10.1007/s10555-011-9320-1
52. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta 2009; 1796: 230–241.
53. Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci (Lond) 2008; 115: 107–127. DOI: 10.1042/CS20080022
54. Peters JM, Morales JL, Gonzales FJ. Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Drug Discov Today Dis Mech 2011; 8: e85–e93. DOI: 10.1016/j.ddmec.2011.11.002
55. Foreman JE, Chang WC, Palkar PS, Zhu B, Borland MG, Williams JL et al. Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer. Mol Carcinog 2011; 50: 884–900. DOI: 10.1002/mc.20757
56. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clinical Exp Metastasis 2010; 27: 83–90. DOI: 10.1007/s10585-010-9305-4
57. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007; 8: R131. DOI: 10.1186/gb-2007-8-7-r131
58. Modica S, Gofflot F, Murzilli S, D'Orazio A, Salvatore L, Pellegrini F et al. The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 2010; 138: 648 e631–612. DOI: 10.1053/j.gastro.2009.09.060
59. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61: 3124–3130.
60. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007; 5: 1263–1275. DOI: 10.1158/1541-7786.MCR-07-0267
61. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 2010. 5.
62. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248–1250. DOI: 10.1038/nbt1210-1248
63. Yang L, Zhang H, Zhou ZG, Yan H, Adell G, Sun XF et al. Biological function and prognostic significance of peroxisome proliferator-activated receptor delta in rectal cancer. Clin Cancer Res 2011; 17: 3760–3770. DOI: 10.1158/1078-0432.CCR-10-2779
64. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065–1079. DOI: 10.1016/j.cell.2007.03.052
65. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 1995; 254: 3–20. DOI: 10.1016/0076-6879(95)54003-2
66. Borland MG, Khozoie C, Albrecht PP, Zhu B, Lee C, Lahoti TS et al. Stable over-expression of PPARβ/δ and PPARγ to examine receptor signaling in human HaCaT keratinocytes. Cell Signal 2011; 23: 2039–2050. DOI: 10.1016/j.cellsig.2011.07.020
67. Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin S et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell proliferation in human HaCaT keratinocytes. Mol Pharmacol 2008; 74: 1429–1442. DOI: 10.1124/mol.108.050609
68. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798–1806. DOI: 10.1038/nprot.2009.191
69. He P, Borland MG, Zhu B, Sharma AK, Amin S, El-Bayoumy K et al. Effect of ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology 2008; 254: 112–117. DOI: 10.1016/j.tox.2008.09.023
70. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH et al. Cellular and pharmacological selectivity of the PPARβ/δ antagonist GSK3787. Mol Pharmacol 2010; 78: 419–430. DOI: 10.1124/mol.110.065508
71. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM et al. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem Biophys Res Commun 2008; 371: 456–461. DOI: 10.1016/j.bbrc.2008.04.086
72. Knutsen GL, Kovatch RM, Robinson M. Gross and microscopic lesions in the female SENCAR mouse skin and lung in tumor initiation and promotion studies. Environ Health Perspect 1986; 68: 91–104.